We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for inf... read more Featured Products: More products

Download Mobile App





Seegene Signs Contract to Deliver Shipment of Four Million Allplex SARS-CoV-2/FluA/FluB/RSV Assay to Brazil

By LabMedica International staff writers
Posted on 24 Feb 2022
Print article
Image: Allplex SARS-CoV-2/FluA/FluB/RSV Assay (Photo courtesy of Seegene, Inc.)
Image: Allplex SARS-CoV-2/FluA/FluB/RSV Assay (Photo courtesy of Seegene, Inc.)

Seegene, Inc. (Seoul, Korea) has signed a supply deal with the Ministry of Health of Brazil to deliver four million COVID-19 tests.

Since January 2022, Brazil has battled a 'twindemic,' a rapid surge in both Flu A and COVID-19 infections due to the rapid spread of the Omicron variant. More seriously, new daily cases of COVID-19 have recently exceeded 280,000 cases, which is the highest figure since the first outbreak of the pandemic. While the country has been seeking to accelerate its quarantine efforts, there is a growing demand for COVID-19 tests as well. In response, Seegene will deliver a shipment of four million Allplex SARS-CoV-2/FluA/FluB/RSV Assay, capable of identifying respiratory viruses including COVID-19, Flu A/B as well as RSV in a single test. This assay is expected to be the optimized solution in Brazil where they are experiencing a rapid surge in both COVID-19 and Flu A cases.

Meanwhile, in January this year, Seegene introduced Allplex SARS-CoV-2 Fast PCR Assay, a new assay optimized for mass testing. This assay can deliver PCR results in just 60 minutes enabling large-scale laboratories to easily scale up the testing volume up to three times without additional instruments. The launch of the new assay is a response to the rapid spread of the latest Omicron variant, globally. The new assay is expected to be the optimized choice for large-scale laboratories and help them immediately expand the testing capacity.

"Seegene is uniquely positioned to respond to the growing global need for COVID-19 and flu testing and we are fully prepared to supply global inventory to help countries around the world as they fight for everyday life to return," said Ho Yi, Chief Sales and Marketing Officer of Seegene.

Related Links:
Seegene, Inc.

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.